Adult Dosing
Hypersecretory conditions/intractable duodenal ulcers
- Intermittent intravenous injection
- Intermittent bolus
- 50 mg (2mL) q6-8 hrs. Dilute ranitidine injection, 50 mg, in 0.9% sodium chloride injection or other compatible IV solution to a concentration no greater than 2.5 mg/mL (20 mL). Inject at a rate no greater than 4 mL/min (5 minutes).
- Max: 400 mg/day
- Intermittent infusion
- 50 mg (2mL) q6-8 hrs. Dilute ranitidine injection, 50 mg, in 5% dextrose injection or other compatible IV solution to a concentration no greater than 0.5 mg/mL (100 mL). Infuse at a rate no greater than 5 to 7 mL/min (15 to 20 minutes).
- Max: 400 mg/day
- Continuous intravenous infusion
- Add ranitidine injection to 5% dextrose injection or other compatible IV solution. Deliver at a rate of 6.25 mg/hr (e.g., 150 mg [6 mL] ranitidine injection in 250 mL of 5% dextrose injection at 10.7 mL/h).
Zollinger-Ellison syndrome
- Diluted to a concentration <2.5 mg/mL with 5% dextrose
- Infuse at a rate of 1 mg/kg/hr
- After 4 hrs or if patient becomes symptomatic increase in increments of 0.5 mg/kg/hr
- Max: 2.5 mg/kg/hr
Pediatric Dosing
Hypersecretory conditions/intractable duodenal ulcers
- Total dose: 2-4 mg/kg in divided dose x q6-8 hrs
- Max: 50 mg x q6-8 hrs
[Outline]
Renal Dose Adjustment (Based on CrCl)
- <50 mL/min: 50 mg q18-24 hrs
- Increase dose to q12 hrs if required; caution advised
- HD: Give dose after dialysis, no supplement
Hepatic Dose Adjustment
- Hepatic impairment: Dose adjustments not defined; caution advised
- Symptomatic response to ranitidine therapy does not preclude the presence of gastric malignancy
- Appropriately adjust dosage in patients with impaired renal function as ranitidine is excreted primarily by the kidney
- Increase in SGPT may occur with the use of ranitidine; monitor SGPT daily in patients receiving IV ranitidine at dosages
100 mg 4 times daily for periods of 5 days or longer - Rare cases of bradycardia have been reported with rapid administration of ranitidine injection in patients with factors predisposing to cardiac rhythm disturbances
- Ranitidine may precipitate acute porphyric attacks in patients with acute porphyria. Avoid use in patients with a history of acute porphyria
Cautions: Use cautiously in
- Hepatic impairment
- Renal impairment
- Elderly or debilitated patients
Pregnancy Category:B
Breastfeeding: Maternal ranitidine would not be expected to cause any adverse effects in breastfed infants. No special precautions are required. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 20 April 2010). According to manufacturer's data, ranitidine is secreted in human milk. Caution should be exercised when ranitidine is administered to a nursing mother.
